Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients - TC Read more about Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients - TC
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - TC Read more about Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) - TC
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer - TC Read more about Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer - TC
Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials - TC Read more about Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials - TC
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation - TC Read more about Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation - TC
Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021 - TC Read more about Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021 - TC
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates - TC Read more about Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates - TC
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis - TC Read more about argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis - TC
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days - TC Read more about Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days - TC
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis - TC Read more about argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis - TC